Chlorhexidine gluconate-coated gel pad dressings for prevention of central venous catheter-related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry-based matched-pair analysis.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 23 08 2023
received: 15 06 2023
accepted: 24 08 2023
medline: 9 11 2023
pubmed: 14 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

Chlorhexidine gluconate (CHG)-coated gel pad dressings for central venous catheter (CVC) may prevent CVC-related bloodstream infections (CRBSI). However, real-world data showing beneficial effects in patients with hematologic malignancies are scarce. In a matched-pair analysis with data from a multicenter CVC registry, non-tunneled jugular and subclavian vein CVC in adults with hematologic malignancies or germ cell tumors (including patients receiving autologous hematopoietic stem cell transplantation [ASCT]) with CHG were compared with non-CHG dressings. The primary endpoint was definite CRBSI rate within 14 days (dCRBSI14) of CVC insertion; secondary endpoints were combined rate of definite or probable CRBSI within 14 days (dpCRBSI14), overall (dpCRBSI), and CRBSI incidences of all estimates. In total, 2070 CVCs were assessed. There was no statistically significant difference in dCRBSI14 (2.3% vs. 3.5%) between patients with and without CHG gel dressings. Likewise, with regards to dpCRBSI14 (6.2% vs. 6.3%) and the overall dpCRBSI rate (9.2% vs. 10.5%), no significant difference was detected. Furthermore, dCRBSI14 incidence (2.0 vs. 3.2/1000 CVC days), dpCRBSI14 incidence (5.4 vs. 5.6/1000 CVC days), and overall CRBSI incidence (5.5 vs. 6.0/1000 CVC days) showed no significant differences. CRBSI rates were not reduced by the use of CHG gel dressings in patients with hematologic malignancies and/or ASCT.

Identifiants

pubmed: 37705250
doi: 10.1111/ejh.14098
doi:

Substances chimiques

chlorhexidine gluconate MOR84MUD8E

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

914-921

Informations de copyright

© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

Références

Mollee P, Jones M, Stackelroth J, et al. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J Hosp Infect. 2011;78(1):26-30. doi:10.1016/j.jhin.2011.01.018
Böll B, Schalk E, Buchheidt D, et al. Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2021;100(1):239-259. doi:10.1007/s00277-020-04286-x
Zakhour R, Chaftari AM, Raad II. Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet Infect Dis. 2016;16(11):e241-e250. doi:10.1016/S1473-3099(16)30213-4
Ziegler MJ, Pellegrini DC, Safdar N. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis. Infection. 2015;43(1):29-36. doi:10.1007/s15010-014-0689-y
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. doi:10.1086/599376
Liñares J. Diagnosis of catheter-related bloodstream infection: conservative techniques. Clin Infect Dis. 2007;44(6):827-829. doi:10.1086/511885
Raad I. Intravascular-catheter-related infections. Lancet. 1998;351(9106):893-898. doi:10.1016/S0140-6736(97)10006-X
Hanna HA, Raad I. Blood products: a significant risk factor for long-term catheter-related bloodstream infections in cancer patients. Infect Control Hosp Epidemiol. 2001;22(3):165-166. doi:10.1086/501885
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103-1110. doi:10.1086/374339
Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32(2):101-114. doi:10.1086/657912
Karpanen TJ, Casey AL, Whitehouse T, Nightingale P, Das I, Elliott TSJ. Clinical evaluation of a chlorhexidine intravascular catheter gel dressing on short-term central venous catheters. Am J Infect Control. 2016;44(1):54-60. doi:10.1016/j.ajic.2015.08.022
Ruschulte H, Franke M, Gastmeier P, et al. Prevention of central venous catheter related infections with chlorhexidine gluconate impregnated wound dressings: a randomized controlled trial. Ann Hematol. 2009;88(3):267-272. doi:10.1007/s00277-008-0568-7
Timsit J-F, Mimoz O, Mourvillier B, et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Respir Crit Care Med. 2012;186(12):1272-1278. doi:10.1164/rccm.201206-1038OC
Wei L, Li Y, Li X, Bian L, Wen Z, Li M. Chlorhexidine-impregnated dressing for the prophylaxis of central venous catheter-related complications: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):429. doi:10.1186/s12879-019-4029-9
Puig-Asensio M, Marra AR, Childs CA, Kukla ME, Perencevich EN, Schweizer ML. Effectiveness of chlorhexidine dressings to prevent catheter-related bloodstream infections. Does one size fit all? A systematic literature review and meta-analysis. Infect Control Hosp Epidemiol. 2020;41(12):1388-1395. doi:10.1017/ice.2020.356
de Campos Pereira Silveira RC, Dos Reis PED, Ferreira EB, Braga FTMM, Galvão CM, Clark AM. Dressings for the central venous catheter to prevent infection in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Support Care Cancer. 2020;28(2):425-438. doi:10.1007/s00520-019-05065-9
Biehl LM, Huth A, Panse J, et al. A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients. Ann Oncol. 2016;27(10):1916-1922. doi:10.1093/annonc/mdw275
Hentrich M, Schalk E, Schmidt-Hieber M, et al. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol. 2014;25(5):936-947. doi:10.1093/annonc/mdt545
O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011;39(4 suppl 1):s1-s34. doi:10.1016/j.ajic.2011.01.003
Ostroff MD, Moureau N, Pittiruti M. Rapid Assessment of Vascular Exit Site and Tunneling Options (RAVESTO): a new decision tool in the management of the complex vascular access patients. J Vasc Access. 2023;24(2):311-317. doi:10.1177/11297298211034306
Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect. 2002;8(5):265-274. doi:10.1046/j.1469-0691.2002.00385.x
Ruxton GD, Neuhäuser M. Review of alternative approaches to calculation of a confidence interval for the odds ratio of a 2 × 2 contingency table. Methods Ecol Evol. 2013;4(1):9-13. doi:10.1111/j.2041-210x.2012.00250.x
Lytras T, Nikolopoulos G, Bonovas S. Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol. 2014;20(7):1858-1870. doi:10.3748/wjg.v20.i7.1858
Sousa B, Furlanetto J, Hutka M, et al. Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol. 2015;26(suppl 5):v152-v168. doi:10.1093/annonc/mdv296
Eggimann P, Pagani J-L, Dupuis-Lozeron E, et al. Sustained reduction of catheter-associated bloodstream infections with enhancement of catheter bundle by chlorhexidine dressings over 11 years. Intensive Care Med. 2019;45(6):823-833. doi:10.1007/s00134-019-05617-x
Wolf HH, Leithäuser M, Maschmeyer G, et al. Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2008;87(11):863-876. doi:10.1007/s00277-008-0509-5
Schalk E, Vehreschild MJGT, Biehl LM. Influence of different definitions of central venous catheter-related bloodstream infections on epidemiological parameters in cancer patients. Infect Control Hosp Epidemiol. 2021;42(4):501-503. doi:10.1017/ice.2020.274
Talbot TR, Stone EC, Irwin K, et al. 2017 Updated Recommendations on the Use of Chlorhexidine-Impregnated Dressings for Prevention of Intravascular Catheter-Related Infections. 2017 Accessed August 11, 2023. https://www.cdc.gov/infectioncontrol/pdf/guidelines/c-i-dressings-H.pdf
Buetti N, Ruckly S, Schwebel C. Chlorhexidine-impregnated sponge versus chlorhexidine gel dressing for short-term intravascular catheters: which one is better? Crit Care. 2020;24(1):458. doi:10.1186/s13054-020-03174-0
Maunoury F, Motrunich A, Palka-Santini M, Bernatchez SF, Ruckly S, Timsit J-F. Cost-effectiveness analysis of a transparent antimicrobial dressing for managing central venous and arterial catheters in intensive care units. PloS One. 2015;10(6):e0130439. doi:10.1371/journal.pone.0130439
Heimann SM, Biehl LM, Vehreschild JJ, Franke B, Cornely OA, Vehreschild MJGT. Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: a cost and resource utilization analysis. Am J Infect Control. 2018;46(9):992-997. doi:10.1016/j.ajic.2018.03.006
Yamashita T, Takamori A, Nakagawachi A, et al. Early prophylaxis of central venous catheter-related thrombosis using 1% chlorhexidine gluconate and chlorhexidine-gel-impregnated dressings: a retrospective cohort study. Sci Rep. 2020;10(1):15952. doi:10.1038/s41598-020-72709-w

Auteurs

Daniel Teschner (D)

Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Department of Hematology, and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Mirjeta Berisha (M)

Department of Hematology and Oncology, Otto-von-Guericke University Magdeburg, Medical Faculty, Magdeburg, Germany.

Jens Panse (J)

Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.

Timo Schmitt (T)

Department of Hematology, and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Hamm Hospital Nahetal, Bad Kreuznach, Germany.

Eva Fiegle (E)

Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.

Jan-Hendrik Naendrup (JH)

Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.
Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.

Julia Neitz (J)

Department of Hematology, and Oncology, Red Cross Hospital Munich, Munich, Germany.

Martin Schmidt-Hieber (M)

Clinic of Hematology, Oncology, Pneumology, and Nephrology, Carl-Thiem-Hospital Cottbus, Cottbus, Germany.

Marcus Hentrich (M)

Department of Hematology, and Oncology, Red Cross Hospital Munich, Munich, Germany.

Boris Böll (B)

Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.
Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.

Enrico Schalk (E)

Department of Hematology and Oncology, Otto-von-Guericke University Magdeburg, Medical Faculty, Magdeburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH